A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy And Safety Of Short-Term Plasma Exchange Followed By Long-Term Plasmapheresis With Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD

Trial Profile

A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy And Safety Of Short-Term Plasma Exchange Followed By Long-Term Plasmapheresis With Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Albumin human (Primary) ; Immune globulin (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms AMBAR
  • Sponsors Grifols
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 01 Aug 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 01 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top